Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CHFR
REST API REST API
Homo sapiens
CHFR is differentially expressed in 237 experiments: 94 organism parts: lung, thymus, ... (92 more);, 162 disease states: normal, cervical carcinoma, ... (160 more);, 83 cell types 450 cell lines 25 compound treatments and 77 other conditions.
Synonyms RNF196, FLJ10796
Orthologs CHFR (Gallus gallus)   CHFR (Bos taurus)   Chfr (Mus musculus)   CHFR (Danio rerio)   Chfr (Rattus norvegicus)   chfr (Xenopus laevis)   CHFR (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ligase activity, cell division, protein binding, protein ubiquitination, mitotic cell cycle, metal ion binding, cell cycle, nucleus, protein polyubiquitination, mitotic cell cycle checkpoint, mitosis, ubiquitin-protein ligase activity, nucleotide binding, ubiquitin-dependent protein catabolic process, zinc ion binding, modification-dependent protein catabolic process, PML body
InterPro Term Znf_RING, FHA_dom
UniProt Accession Q96EP1, F5H829, F5H7R8, F5GWT6, F5GWH4, F5H5P5, F5H375
Search EB-eye ENSG00000072609
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (44 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
AGS
2
E-MTAB-37, E-GEOD-15460
HT1080
2
E-GEOD-20089, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
SW480
2
E-GEOD-18005, E-MEXP-1014
444 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (36 experiments)

Factor Value U/D Experiments
monocyte
3
E-GEOD-22373, E-MEXP-583, E-GEOD-11755
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
testis - leydig cell
2
E-AFMX-5, E-TABM-145
SCC
1
E-GEOD-19188
parental foreskin cells
1
E-GEOD-20033
77 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-1121, E-GEOD-12254, ... (41 experiments)

Factor Value U/D Experiments
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
colon carcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-MTAB-62
cervical carcinoma
1
2
E-MTAB-62, E-MEXP-1331, E-MTAB-37
no tendon xanthomas
1
E-MTAB-62
156 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-5741, E-GEOD-5824, E-GEOD-3720, E-MEXP-1958, ... (15 experiments)

Factor Value U/D Experiments
none
2
3
E-MEXP-1958, E-GEOD-4600, E-GEOD-5824, E-GEOD-5741, E-MEXP-1230 ... (5 experiments)
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
phoshate buffered saline
1
E-GEOD-3720
unknown
1
E-GEOD-7307
Cxcl12
1
E-GEOD-7307
19 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-20499, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-TABM-26, E-GEOD-22148, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, E-MEXP-563

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-GEOD-17347, E-GEOD-21243 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657, E-GEOD-21612, E-GEOD-20504, ... (6 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400, E-GEOD-6802 ... (5 experiments)

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-4600

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-3697, E-MEXP-1857

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-6532, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.303 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM